| First Author | Luo JH | Year | 2024 |
| Journal | Cell Metab | Volume | 36 |
| Issue | 10 | Pages | 2262-2280.e5 |
| PubMed ID | 39293433 | Mgi Jnum | J:359869 |
| Mgi Id | MGI:7750160 | Doi | 10.1016/j.cmet.2024.08.009 |
| Citation | Luo JH, et al. (2024) PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disorders. Cell Metab 36(10):2262-2280.e5 |
| abstractText | Adipose tissue macrophages (ATMs) play important roles in maintaining adipose tissue homeostasis and orchestrating metabolic inflammation. Given the extensive functional heterogeneity and phenotypic plasticity of ATMs, identification of the authentically pathogenic ATM subpopulation under obese setting is thus necessitated. Herein, we performed single-nucleus RNA sequencing (snRNA-seq) and unraveled a unique maladaptive ATM subpopulation defined as ATF4(hi)PDIA3(hi)ACSL4(hi)CCL2(hi) inflammatory and metabolically activated macrophages (iMAMs), in which PDIA3 is required for the maintenance of their migratory and pro-inflammatory properties. Mechanistically, ATF4 serves as a metabolic stress sensor to transcribe PDIA3, which then imposes a redox control on RhoA activity and strengthens the pro-inflammatory and migratory properties of iMAMs through RhoA-YAP signaling. Administration of Pdia3 small interfering RNA (siRNA)-loaded liposomes effectively repressed adipose inflammation and high-fat diet (HFD)-induced obesity. Together, our data support that strategies aimed at targeting iMAMs by suppressing PDIA3 expression or activity could be a viable approach against obesity and metabolic disorders in clinical settings. |
